.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical evidence suggests that transdermal estradiol prostate cancer treatment serves as a robust alternative to standard luteinizing hormone-releasing hormone (LHRH) agonists. According to the latest findings from the Phase 3 PATCH trial, this approach provides effective androgen deprivation while significantly altering the toxicity profile for patients. Historically, clinicians used oral estrogen for prostate cancer, but it was largely abandoned due to high cardiovascular and thromboembolic risks. However, transdermal administration avoids the first-pass hepatic metabolism, potentially mitigating these concerns.
In this non-inferiority trial, researchers randomized 1,360 men with locally advanced prostate cancer to receive either transdermal estradiol (tE2) patches or standard LHRH agonists. The results showed a 3-year metastasis-free survival (MFS) of 87.1% in the tE2 group and 85.9% in the LHRH agonist group. Consequently, the study confirmed that tE2 is statistically non-inferior to conventional hormonal therapy. Furthermore, both treatment arms successfully maintained castrate levels of testosterone in 85% of the patients.
While the oncological efficacy was similar, the side-effect profiles varied considerably between the two groups. Men treated with transdermal estradiol prostate cancer patches reported a significantly lower incidence of hot flashes compared to those on LHRH agonists (44% vs. 89%). Additionally, tE2 therapy appeared to preserve bone mineral density and offer better metabolic profiles. Conversely, the incidence of gynecomastia was twice as high in the tE2 arm, affecting 85% of men. Despite this, there were no significant differences in cardiovascular morbidity or mortality between the two groups. Therefore, clinicians can consider tE2 patches as a cost-effective and patient-friendly option, especially for those prioritizing bone health and vasomotor symptom relief.
Yes, the Phase 3 trial demonstrated that 3-year metastasis-free survival was nearly identical between the two groups (87.1% for estradiol vs. 85.9% for LHRH agonists), meeting the criteria for non-inferiority.
Estradiol patches cause fewer hot flashes and help maintain bone density but result in significantly higher rates of gynecomastia compared to LHRH agonists.
No, the study found no evidence of increased cardiovascular mortality or thromboembolic events with patches, as the transdermal route avoids the liver's first-pass effect on clotting factors.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Phase 3 trial confirms that transdermal estradiol patches are a non-inferior, cost-effective alternative to LHRH agonists for locally advanced prostate ca...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
